response-2 5-year follow-up update: ruxolitinib vs bat in polycythemia vera without splenomegaly
Published 2 years ago • 127 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
1:32
response-2: 5-year follow-up of second-line ruxolitinib therapy for pv
-
2:14
long-term 5-year data continues to show response to ruxolitinib in polycythemia vera
-
2:49
the 5-year update on the comfort-ii clinical trial of ruxolitinib
-
3:34
a response to ruxolitinib: update on 4-year trial follow-up
-
1:56
5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
-
10:56
identifying and communicating your polycythemia vera (pv) symptoms
-
3:12
diagnosed early in life with polycythemia vera: todd’s mpn story
-
3:34
taking charge of her polycythemia vera: aimee’s journey with pv
-
1:12
contemporary challenges in polycythemia vera management
-
1:13
updated findings after 5-year follow-up for ruxolitinib in pv
-
2:54
an update on the use of idasanutlin in polycythemia vera
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
14:13
guide to uploading 2x2 photo and laboratory result in qchealth certificate online application
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
4:42
response-2 trial: ruxolitinib for pv
-
1:54
ongoing trials in polycythemia vera: low-pv & verify
-
2:38
ongoing data from the phase 3 response trial of ruxolitinib for polycythemia vera
-
1:30
the patient perspective of polycythemia vera and second-line treatment options
-
44:01
instent restenosis: approach and detailed cases with ivus/oct
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
10:20
new guidelines for the treatment and management of polycythemia vera
-
3:43
updated results from manifest arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis